Analysts at HSBC stated that the exceptional growth momentum previously seen in Unilever's health brands, Liquid IV and Nutrafol, is now returning to normal levels. This development is expected to lead to a slowdown in the overall business growth of Unilever in the United States.

The analysts noted that although the consumer goods giant anticipates improved performance in the fourth quarter, ongoing competition in the health segment remains a concern.

They further commented, "This could deprive Unilever of a key factor that had previously enabled it to outperform the broader market." At the same time, market expectations are leaning toward an acceleration in growth within emerging markets by 2026. Shares of Unilever declined 0.1% to £54.27.